Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Three-Year Wait? Biocon Set To Weigh US Eylea Judgment

Regulatory Exclusivity For Blockbuster Biologic Expires In Four Months

Executive Summary

A bench trial closely watched since June last year has delivered a verdict – although it’s not a completely happy picture for US Eylea (aflibercept) biosimilar hopeful Biocon.

You may also be interested in...



Amgen Hit With US Eylea Suit Ahead Of Looming Biosimilar Date

Regeneron is continuing to keep the pressure on would-be biosimilar sponsors for its mammoth Eylea (aflibercept) brand, suing biosimilar sponsor Amgen for alleged patent infringement on the back of a recent favorable verdict over Biocon.

Amgen Confirms US Aflibercept Filing As Regeneron Awaits Biocon Trial Fate

Amgen has thrown its hat in the ring to launch a US biosimilar to Regeneron’s Eylea eye-disease blockbuster, as all eyes remain on the outcome of a key patent-infringement trial between Biocon and the originator.

Viatris Believes Eylea Biosimilar Candidate Is First To Reach US FDA’s Desk

Viatris provided several key updates for its biosimilar pipeline during the company’s Q3 earnings call, including for its biosimilar Eylea and Botox candidates, as well as disclosing another key early-stage asset.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153198

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel